Skip to main content
SLU:s publikationsdatabas (SLUpub)

Forskningsartikel2017Vetenskapligt granskad

Die Wirkung von Pimobendan bei Hunden mit praklinischer myxomatoser Mitralklappen- erkrankung und Kardiomegalie: Die EPIC-Studie - Eine randomisierte klinische Studie

Boswood, Adrian; Haeggstroem, Jens; Gordon, Sonya G.; Wess, Gerhard; Stepiens, Rebecca L.; Oyama, Marc A.; Keene, Bruce W.; Bonagura, John; MacDonald, Kristin A.; Patteson, Marc; Smith, Sarah; Fox, Philip R.; Sanderson, Karen; Woolley, Richard; Szatmari, Viktor; Menaut, Pierre; Church, Whit M.; O'Sullivan, M. Lynn; Jaudon, Jean-Phillippe; Kres-Ken, Jan-Gerd;
Visa fler författare


Background Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown.Hypothesis/Objectives Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia.Animals 360 client-owned dogs with MMVD with left atrial-to-aortic ratio >= 1.6, normalized left ventricular internal diameter in diastole >= 1.7, and vertebral heart sum >10.5.Methods Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia.Results Median time to primary endpoint was 1228.days (95% CI: 856 -NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P =.0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P =.012).Conclusions and Clinical Importance Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit.


asymptomatic; echocardiography; endocardiosis; heart failure; mitral regurgitation; prevention; treatment; vertebral; heart sum

Publicerad i

2017, Volym: 62, nummer: 2, sidor: 64-87